EGFR and cancer: As erlotinib is an EGFR TKI, it seems likely that the patients with an EGFR positive cancer genotype would benefit more from treatment with erlotinib than the patients with an EGFR wild type genotype, making it difficult to evaluate the actual effect of the added onartuzumab or capmatinib treatment.